United States-based Merck's Keytruda (pembrolizumab) in combination with pemetrexed (Alimta) plus platinum chemotherapy has improved overall survival and progression-free survival of a certain type of lung cancer patients in a phase three trial, it was reported yesterday.
Both overall survival and progression-free survival were defined to be the dual primary endpoints of the pivotal late-stage trial named KEYNOTE-189.
The trial evaluated the combination of Keytruda, Lilly's pemetrexed and platinum chemotherapy made up of cisplatin or carboplatin as a first-line treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC). The Keytruda regimen was assessed in comparison to pemetrexed and cisplatin or carboplatin alone in 614 NSCLC patients, regardless of PD-L1 expression. According to Merck, the safety profile of Keytruda in the combination was on par with previous observations.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval